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Purpose: To evaluate the correlation between quality of vision (QOV) and visual function in 
glaucoma patients.
Patients and methods: The relationship between QOV and visual function was investigated 
in 200 Japanese glaucoma patients. QOV was assessed using the Japanese version of the 25-item 
National Eye Institute Visual Function Questionnaire. The better eye and the worse eye were 
defined based on the mean deviation (MD) value of the Humphrey Field Analyzer program 30-2. 
A single linear regression analysis was applied to assess the relationship.
Results: The lowest subscale score was observed in general health followed by general vision 
and driving. Visual acuity and the central 10° MD value in the better eye and the central 30° MD 
value in the worse eye were highly correlated with QOV . Threshold MD values at which patients 
began to have lower QOV ranged from −2 to −12 dB in the better eye and from −7 to −16 dB 
in the worse eye.
Conclusion: Loss of visual function in both the better and the worse eye is significantly 
  correlated to QOV . QOV of glaucoma patients begins to decrease in the early stages of visual 
field defects.
Keywords: glaucoma, 25-item National Eye Institute Visual Function Questionnaire, visual 
field, visual acuity, quality of vision
Introduction
Glaucoma is the third leading cause of blindness worldwide followed by cataract and 
trachoma. It is responsible for the loss of vision in 5.2 million people1 (ie, 15% of 
the total cases of blindness) and is also a primary cause of visual impairment even in 
advanced countries. In Japan, glaucoma is the main cause of visual disability in 307,000 
people. The Tajimi Study,2 a population-based epidemiological survey in Tajimi in 
central Japan in 2001, revealed that 5% of people over 40 years of age were affected 
by glaucoma. As long as the treatment of glaucoma is able only to   decelerate the dis-
ease and is not able to recover visual functionality, it is critical that patients are treated 
before their quality of life (QOL) deteriorates.
Conventional clinical assessments of visual function, such as visual acuity and 
visual field tests, do not fully reflect the impact of visual disabilities on daily life. 
An objective estimation of an individual’s QOL is not simple, because QOL is affected 
by many factors, including lifestyle, occupation, gender, and age. However, the 
recently developed scoring system for QOL, which is based on the 25-item National 
Eye Institute Visual Function Questionnaire (NEI VFQ-25), has been   successfully 
applied to quantitatively evaluate the vision-specific QOL (quality of vision [QOV]) of Clinical Ophthalmology 2011:5
Table 1 Ophthalmological data for the glaucoma patients
Better eye (±SD) Worse eye (±SD)
Log10MAr BCVA −0.03 ± 0.13  
(−0.07 to 0.39)
0.12 ± 0.62  
(−0.07 to LS)
Foveal threshold (dB) 33.93 ± 3.50  
(24 to 43)
31.59 ± 7.43  
(0 to 38)
hFA 30-2 MD (dB) −8.33 ± 8.36  
(3.74 to −28.68)
−14.17 ± 8.52  
(1.05 to −30.96)
hFA 10-2 MD (dB) −10.41 ± 9.10  
(1.8 to −31.62)
−16.49 ± 9.17  
(−0.30 to −32.98)
Abbreviations:  BCVA,  best-corrected  visual  acuity;  hFA,  humphrey  Field 
Analyzer; Log10MAr, logarithm of the minimum angle of resolution; LS, light sense; 
MD, mean deviation; SD, standard deviation.
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patients with different eye diseases.3,4 The NEI VFQ-25 has 
been translated and is used around the world.5–8 The NEI 
VFQ-25 has proved its validity and reliability for assessing 
QOV among patients with diabetic retinopathy,10 retinitis 
pigmentosa,11 age-related macular degeneration,12 and 
glaucoma.13,14 In the current study, we used the Japanese 
version of the NEI VFQ-259 to analyze the relationship 
between the loss of visual function and QOV in glaucoma 
patients. The Japanese version of the NEI VFQ-25 has also 
been proved to have both reliability and validity in glaucoma 
patients.9 In this study, we focused on the impact of glaucoma 
on the patient’s QOV . Furthermore, we investigated the mean 
deviation (MD) threshold at which glaucoma patients begin 
to have difficulty with their vision.
Patients and methods
Study population
We evaluated 200 consecutive Japanese patients (103 men and 
97 women) with glaucoma during follow-up visits at Niigata 
University Medical and Dental Hospital in Japan or its facili-
ties. Glaucoma subtypes were determined by clinical exami-
nation including intraocular pressure, slit lamp examination, 
and gonioscopic examination. Of these 200 patients, 91 pre-
sented with normal tension glaucoma, 74 with primary open-
angle glaucoma, 12 with secondary glaucoma, eight with 
developmental glaucoma, eight with primary   angle-closure 
glaucoma, and seven with overlapping types of glaucoma. 
All patients clinically diagnosed with glaucoma had met one 
of the following criteria: i)   reproducible visual field defects 
using program 30-2 of the Humphrey® Field Analyzer (HFA; 
Carl Zeiss, Dublin, CA, USA); or ii)   glaucomatous excavation 
of the optic nerve head. Patients with underlying pathological 
ocular conditions were excluded; these conditions included 
  apparent senile cataract (eg, greater than grade 2 in Emery–
Little classification or   posterior subcapsular cataract) and 
cerebral conditions that could cause visual field loss. Patients 
who underwent intraocular surgery within the last 6 months 
were also excluded from the study.
Questionnaire
We asked each patient to complete a self-assessment of 
their QOV with the Japanese version of the NEI VFQ-25 
(a total of 38 questions with 25 items and 13 options), 
which addresses aspects of visual ability with 12 subscales. 
These subtypes include the general health, general vision, 
ocular pain, near vision, distance vision, social function, 
mental health, role limitations, dependency, driving, color 
vision, and peripheral vision of the patient. Each subscale 
is a single-item question with five possible answers rang-
ing from grade 1 to 5 or 6. Each subscale grade was then 
converted to a possible score ranging from 0 to 100, with 
a higher score indicating better QOV. A composite score, 
which was the mean score of all the subscales except for 
general health, was also calculated.
evaluating visual function
Data on visual function were obtained from bilateral eyes. The 
best-corrected visual acuity was evaluated at baseline and at 
follow-up. Data that were collected at the same time as this 
study or within 6 months were used. Decimal units of visual 
acuity were converted to the mean visual acuity of the logarithm 
of the minimum angle of resolution (log10MAR). The central 
visual field was tested using either full-threshold or sita-standard 
HFA programs 30-2 and 10-2. Scores (dB) of MD and foveal 
threshold were used to assess the severity of visual field loss. 
The determination of both the better eye and the worse eye was 
based on the value of MD from HFA program 30-2.
Data analysis
A single linear regression analysis was applied to assess 
the relationship between visual function and scores on the 
NEI VFQ-25 questionnaire. Twelve subscale scores and 
the composite score from the NEI VFQ-25 were used as 
independent variables for comparison with the dependent 
variables of visual acuity, MD scores from programs 30-2 
and 10-2, and foveal threshold.
The patients were divided into two groups: one group 
included patients aged younger than 60 years and the other 
group aged 60 or older than 60 years. A nonparametric 
analysis (Mann–Whitney U test) was used to decide which 
age group had a better QOV .Clinical Ophthalmology 2011:5
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Figure 1 Average subscale scores for glaucoma patients on a Japanese version of the 25-item national eye institute Visual Function Questionnaire.
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We defined subscale scores less than 59 as “low”, in order 
to determine the MD threshold value of which   glaucoma 
patients begin to feel difficulties in their day-to-day activities. 
For this analysis, we divided patients into a higher score group 
(higher than 60) and a lower score group (less than 59) for 
each subscales. A nonparametric analysis (Chi-square test) 
was used to evaluate this data.
P values less than 0.001 were considered significant. 
Correlations were denoted as “good” when the correlation 
coefficient was between 0.4 and 0.6, “moderate” when 
between 0.2 and 0.39, and “poor” when less than 0.2. All 
statistical analyses were carried out using statistical analysis 
software SPSS® Version 14 for Windows® (SPSS, Chicago, 
IL, USA).
Results
The mean best-corrected visual acuities, foveal threshold, 
MD scores from program 30-2, and MD scores from 
program 10-2 for the better and worse eyes are shown in 
Table 1. The average scores for the 12 subscales and the 
composite are shown in Figure 1. In summary,   general 
health (56.68 ± 15.37) scored the lowest of all of the 
  variables, followed by   general vision (66.55 ± 16.37), driving 
(66.98 ± 25.75), and peripheral vision (67.38 ± 23.67).
Higher correlations were found between QOV and 
visual functions for vision-specific subscales, whereas 
no   significant correlations were observed for universal 
  subscales, including general health and ocular pain. Loss 
of visual function, including visual acuity and visual field, Clinical Ophthalmology 2011:5
Table 2 P values and correlation coefficients for single linear regression analysis of the association between visual function and visual 
disability indices in the better eye
Log10MAR BCVA HFA 30-2 HFA 10-2
Fovea (dB) MD (dB) MD (dB)
general health 0.029 (0.155) 0.014 (0.177) 0.002 (0.216) 0.193 (0.120)
general vision ,0.001 (0.297) ,0.001 (0.298) ,0.001 (0.467)a ,0.001 (0.556)a
Ocular pain 0.055 (0.134) 0.076 (0.128) 0.049 (0.141) 0.371 (0.082)
near vision ,0.001 (0.380) ,0.001 (0.395) ,0.001 (0.465)a ,0.001 (0.541)a
Distance vision ,0.001 (0.372) ,0.001 (0.424)a ,0.001 (0.474)a ,0.001 (0.540)a
Social function 0.003 (0.210) ,0.001 (0.331) ,0.001 (0.371) ,0.001 (0.478)a
Mental health ,0.001 (0.269) ,0.001 (0.315) ,0.001 (0.497)a ,0.001 (0.543)a
role limitations ,0.001 (0.373) ,0.001 (0.410)a ,0.001 (0.460)a ,0.001 (0.508)a
Dependency ,0.001 (0.274) ,0.001 (0.348) ,0.001 (0.420)a ,0.001 (0.494)a
Driving ,0.001 (0.391) 0.001 (0.379) ,0.001 (0.473)a ,0.001 (0.525)a
Color vision 0.020 (0.168) ,0.001 (0.252) ,0.001 (0.323) ,0.001 (0.336)
Peripheral vision 0.008 (0.191) ,0.001 (0.200) ,0.001 (0.437)a ,0.001 (0.437)a
Composite ,0.001 (0.354) ,0.001 (0.393) ,0.001 (0.528)a ,0.001 (0.581)a
Note: aCorrelation coefficients of $0.4.
Abbreviations: BCVA, best-corrected visual acuity; hFA, humphrey Field Analyzer; Log10MAr, logarithm of the minimum angle of resolution; MD, mean deviation.
Table 3 P values and correlation coefficients for single linear regression analysis of visual function and visual disability indices in the 
worse eye
Log10MAR BCVA HFA 30-2 HFA 10-2
Fovea (dB) MD (dB) MD (dB)
general health 0.303 (0.073) 0.366 (0.066) ,0.001 (0.249) 0.005 (0.255)
general vision ,0.001 (0.274) ,0.001 (0.348) ,0.001 (0.464)a ,0.001 (0.530)a
Ocular pain 0.994 (0.001) 0.230 (0.087) 0.043 (0.146) 0.230 (0.110)
near vision ,0.001 (0.288) ,0.001 (0.320) ,0.001 (0.442)a ,0.001 (0.488)a
Distance vision ,0.001 (0.401)a ,0.001 (0.372) ,0.001 (0.506)a ,0.001 (0.519)a
Social function ,0.001 (0.251) ,0.001 (0.282) ,0.001 (0.379) ,0.001 (0.361)
Mental health 0.001 (0.308) ,0.001 (0.344) ,0.001 (0.522)a ,0.001 (0.530)a
role limitations ,0.001 (0.243) ,0.001 (0.265) ,0.001 (0.408)a ,0.001 (0.430)a
Dependency ,0.001 (0.278) ,0.001 (0.304) ,0.001 (0.431)a ,0.001 (0.494)a
Driving 0.007 (0.391) ,0.001 (0.379) ,0.001 (0.473)a ,0.001 (0.426)a
Color vision ,0.001 (0.198) 0.006 (0.200) ,0.001 (0.343) ,0.001 (0.363)
Peripheral vision ,0.001 (0.207) 0.001 (0.239) ,0.001 (0.442)a ,0.001 (0.370)
Composite ,0.001 (0.311) ,0.001 (0.366) ,0.001 (0.540)a ,0.001 (0.541)a
Note: aCorrelation coefficients of $0.4.
Abbreviations: BCVA, best-corrected visual acuity; hFA, humphrey Field Analyzer; Log10MAr, logarithm of the minimum angle of resolution; MD, mean deviation.
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in both eyes was significantly correlated with decreased 
general vision, near vision, distant vision, mental health, 
role limitations, dependency, driving, and composite scores. 
Correlation coefficients in eight subscales and the compos-
ite were higher in the worse eye than in the better eye. Visual 
field was the only variable that was significantly correlated 
with social function, color vision, and peripheral vision. 
Neither visual acuity nor visual field was significantly 
  correlated with general health and ocular pain (Tables 2 
and 3). The results of the correlation coefficients for the 
single linear regression analysis between HFA program 
30-2 and 10-2 were slightly greater in program 10-2, but 
they were similar overall. The visual field impairment 
measured by the HFA program 30-2 was highly correlated 
with the composite score for both better and worse eyes 
(Figures 2 and 3). A scatter plot of composite scores showed 
a monotonic trend. As the MD worsened, the subscale scores 
decreased along with it.
The relationship between age and average subscale scores 
revealed that younger patients (,60 years old) generally 
had better QOV . Scores were higher in younger patients for 
all subscales except for general vision and the composite Clinical Ophthalmology 2011:5
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Figure 3 Composite 25-item national eye institute Visual Function Questionnaire 
scores in the worse eye (y-axis) are correlated with mean deviation scores from 
humphrey Field Analyzer program 30-2 (x-axis).
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(Figure 4). A significant difference between younger and 
older patients was observed in social function and color 
vision. There was not a significant difference in either visual 
acuity or MD scores between the younger age group and 
older one (Table 4).
The threshold MD scores at which the patients began 
to feel some difficulty with QOV were determined for all 
12 subscales, as well as for the composite score. The   threshold 
ranged from −2 dB to −12 dB for the better eye and from −7 dB 
to −16 dB for the worse eye. Three subscales in both the better 
eye and the worse eye, including general health, ocular pain 
and color vision, showed no significant threshold when MD 
value decreased to as low as −25dB (Table 5).
Discussion
In this study, we used the NEI VFQ-25 to evaluate QOV 
in glaucoma patients. Most of the subscale scores and the 
composite score were significantly associated with the 
deterioration of visual acuity and the visual field. Among 
the 12 subscales and the composite, the lowest scores were 
observed in general health, followed by general vision, driv-
ing, and peripheral field. These results are consistent with 
previous studies of QOV in glaucoma patients.15–17 When 
patients were divided into two groups based on age, the 
lowest scores were still observed in general health in both 
the young and old groups of patients. This preliminary result 
may reflect the substantial psychological burden experienced 
by glaucoma patients.
Glaucoma patients are said to have difficulties with 
driving,13 and driving received the third worst score in our 
study. Our results of MD value thresholds showed that many 
patients begin to have lower scores of NEI VFQ-25 in early 
stages of visual field defects. One report concluded that 
glaucoma patients who have less than a −4.0 dB MD value 
in the worse eye are more likely to fail to see a pedestrian 
than those with a better visual field.18 Furthermore, glare 
and dark adaptation were significantly associated with more 
severe visual field loss in glaucoma patients.19 The ability 
to see at low luminance levels is required for night driving; 
therefore, glaucoma patients who have reduced contrast 
sensitivity20 will likely be distracted. Because peripheral 
vision, in addition to central vision, is required for driving, 
lower scores in that variable may be responsible for the low 
scores in driving. Haymes et al investigated on-road perfor-
mance in glaucoma patients with a slight to moderate visual 
field defect.18 They concluded that the worse-eye MD was 
the most correlated factor with driving among other visual 
functions, including visual acuity, contrast sensitivity, visual 
field, and binocular visual field. However, we did not find 
a similar difference between the better eye and worse eye 
in the central 30° visual field in driving in this study. MD 
threshold scores in the better and worse eyes indicate that 
driving performance may begin to deteriorate in the early 
stages of visual field defect.
y = 0.9804x + 86.556
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Figure 2 Composite 25-item national eye institute Visual Function Questionnaire 
scores in the better eye (y-axis) are correlated with mean deviation scores from 
humphrey Field Analyzer program 30-2 (x-axis).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Aging is one of the many factors that affect QOV, 
although the impact of a patient’s age on QOV is 
controversial. In this study, we divided patients into two 
groups at the age of 60 years. Because the retirement age 
is 60 years in general in Japan, we divided the group at 
the age of 60 years in order to differentiate people who are 
actively at work and those who are not. Magacho et al21 
reported that younger patients have better QOV, whereas 
Asano et al16 found that older patients had better QOV. Our 
results were similar to those of Magacho et al,21 that the 
younger patient group had a better QOV in the composite 
and all subscales except for general vision. Although the 
MD scores of HFA program 30-2 did not reveal a dif-
ference between the two groups, the older patient group 
tended to have worse visual acuity in the better eye. This 
may suggest that the age-related deterioration of visual 
acuity, such as senile cataracts, is a potential cause of 
decreased NEI VFQ-25 scores. There was not a significant 
difference between the QOV of older patients and younger 
patients; significant differences were observed only for 
social function and color vision scores. When comparing 
older and younger patients in terms of QOV, these results 
suggest that younger people may adapt better to the dete-
rioration of visual function. Patients’ lifestyles, residence, 
clinical course, and social functions might also be factors 
that affect people’s QOV .
Although it is essential to evaluate each eye when 
determining the severity of the glaucoma, it is more 
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Figure 4 Average subscale scores for young and old glaucoma patients.
Note: *P , 0.001.Clinical Ophthalmology 2011:5
Table 4 Visual function data in young and old glaucoma patients
Aged ,60 years 
Mean ± SD
Aged $60 years 
Mean ± SD
P value
Age 48.52 ± 8.00 69.45 ± 5.77 ,0.001
Better eye
  BCVA −0.04 ± 0.15 −0.02 ± 0.11 0.021
  MD of hFA 30-2 −8.23 ± 8.14 −8.21 ± 8.80 0.827
Worse eye
  BCVA 0.26 ± 0.91 0.03 ± 0.30 0.965
  MD of hFA 30-2 −14.26 ± 8.56 −14.22 ± 8.52 0.888
Abbreviations: BCVA, best-corrected visual acuity; hFA, humphrey Field Analyzer; 
MD, mean deviation; SD, standard deviation.
Table 5 MD threshold scores from hFA program 30-2 of which 
the number of the patients becomes significantly higher to have 
lower subscale scores. The definition of the lower subscale score 
was determined as lower than 59
Better eye Worse eye
MD (dB) P value MD (dB) P value
general health −25 0.569 −25 0.038
general vision −4a ,0.001a −12a ,0.001a
Ocular pain −25 0.186 −25 0.751
near vision −6a ,0.001a −12a ,0.001a
Distance vision −2a ,0.001a −7a ,0.001a
Social function −4a ,0.001a −15a ,0.001a
Mental health −25 0.507 −8a ,0.001a
role limitations −12a ,0.001a −15a ,0.001a
Dependency −12a ,0.001a −16a ,0.001a
Driving −6a ,0.001a −8a ,0.001a
Color vision −25 0.117 −25 0.089
Peripheral vision −4a ,0.001a −8a ,0.001a
Composite −3a ,0.001a −12a ,0.001a
Note: aP value , 0.001.
Abbreviations: hFA, humphrey Field Analyzer; MD, mean deviation.
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appropriate to investigate QOV using binocular visual 
function in order to assess patients’ QOV more naturally. 
The Esterman binocular visual field test was developed 
for evaluating the total field and is able to provide a more 
appropriate visual field score without using a difficult 
formula.22,23 However, the Esterman test does not assess 
binocular summation,24 and the relationship between the 
Esterman visual field test and the NEI VFQ-25 (r = 0.44; 
VFQ overall) is reported to be lower than that of the 
combination of two monocular fields (r = 0.48) or MD 
in the worse eye (r = 0.49).25,26 Several studies have com-
pared the better eye and the worse eye in order to explore 
which eye contributes more to QOV in glaucoma patients. 
Gutierrez et al27 used the Advanced Glaucoma Interven-
tion Study (AGIS) score to calculate the visual field and 
concluded that more visual field defects in the better eye 
were associated with VFQ-25 than in the worse eye. A 
relationship between the VFQ-25 and AGIS scores was 
also well documented in a study by Jampel et al, which 
did not reveal a difference between the better eye and the 
worse eye.26 Some factors, including the scoring program 
of the visual field, the number of VFQ-25 items used, and 
the data collection methods, may have led to differences 
between the statistical results. Our results showed that the 
score of the VFQ-25 correlated the most with the MD of 
HFA program 30-2 in the worse eye but was not much dif-
ferent from the score of the better eye. In contrast, visual 
acuity and the MD of HFA program 10-2 correlated higher 
in the better eye than in the worse eye, which has also 
been reported by other investigators.27 The significance 
of the visual function of each eye varies between stud-
ies. For example, some   studies demonstrate significant 
correlations between the better eye and QOV ,28,29 whereas 
others show better correlations in the worse eye.30,31 The 
significance of the better eye and the worse eye has not 
been fully understood, and further   studies may be needed 
to reach a conclusion. In our study, the   better eye was more 
important in terms of visual acuity and the central 10° 
visual field, whereas the worse eye was more important in 
the central 30° visual field. From this result, we presumed 
that the central vision-related QOL depends on the better 
eye, whereas the more peripheral vision-related QOL may 
depend on the worse eye.
To the best of our knowledge, this report is the first to 
  provide a threshold MD value that describes when patients 
begin to feel a decrease in their QOV due to glaucoma. 
We found that the thresholds ranged from −2 dB to −12 dB 
in the better eye and from −7 dB to −16 dB in the worse eye, 
which supports previous reports that vision-specific QOV 
begins to decline with mild visual field defects and that 
composite scores begin to decrease when patients have HFA 
program 30-2 MD values less than −5 dB.16 The HFA program 
30-2 is the most commonly used clinical assessment tool; 
thus, the significant correlation between HFA program 30-2 
and QOV should generate reliable and useful ideas for further 
treatment. Our threshold data include specific MD values for 
each eye. Although we defined scores below 59 as low, the 
conclusions drawn by other studies may vary based on how the 
low scores are defined. It may be premature to conclude that 
the threshold data indicate when further treatment should be 
initiated. However, our data provide evidence that patients feel 
some visual disturbances in the early stages of glaucoma.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In conclusion, the current study suggests that impaired 
visual function in both eyes of patients with glaucoma 
is well correlated with impaired subscale scores on the 
NEI VFQ-25. Although aging is likely to reduce subscale 
scores, different lifestyles and social functions may also 
affect the patient. Thus, subscale scores should be assessed 
in the context of each individual patient. As long as visual 
acuity is well preserved until the late stages of glaucoma, 
it is essential to evaluate the appropriate relationship 
between glaucomatous visual field defects and QOV 
before impairment of vision is completed. Assessing 
QOV in glaucoma patients at early stages of the disease 
is critical for determining when further treatment should 
be given in order to maintain good QOV. The QOV of 
glaucoma patients begins to decrease at the early stages 
of visual field loss, which are easily detectable using the 
NEI VFQ-25. These findings showed that estimating QOV 
of glaucoma patients with the NEI VFQ-25 is effective 
and properly reflects impaired visual function. The results 
will be able to offer clinicians in providing good under-
standing of patients’ QOV and benefit patients in most 
clinical settings in order to ensure treatment strategy at 
an appropriate timing.
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